Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M343Revenue $M0.4Net Margin (%)-23,400.8Altman Z-Score10.3
Enterprise Value $M233EPS $-1.6Operating Margin %-24,307.1Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.4Pre-tax Margin (%)-23,399.5Higher ROA y-yY
Price/Book2.610-y EBITDA Growth Rate %-15.3Quick Ratio12.0Cash flow > EarningsY
Price/Sales8465-y EBITDA Growth Rate %-15.7Current Ratio12.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-52.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-57.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M59.5ROIC % (ttm)-425.1Gross Margin Increase y-yN

Gurus Latest Trades with ARWR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARWRGeorge Soros 2014-06-30 Sold Out -0.01%$9.79 - $18.28
($13.09)
$ 5.77-56%Sold Out0
ARWRGeorge Soros 2014-03-31 Buy 0.01%$9.92 - $26.57
($17.36)
$ 5.77-67%New holding44,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARWR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ARWR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lewis David L.Chief Scientific Officer 2015-01-05Sell15,000$8.01-27.97 view
Anzalone Christopher RichardPresident and CEO 2014-10-15Buy16,000$6.32-8.7 view
Anzalone Christopher RichardPresident and CEO 2014-10-15Buy16,000$6.32-8.7 view
McKenney CharlesDirector 2014-10-01Sell2,500$14.7-60.75 view
Lewis David L.Chief Scientific Officer 2014-09-30Sell15,000$15.02-61.58 view
GIVEN DOUGLAS BDirector 2014-09-26Sell2,000$15.24-62.14 view
GIVEN DOUGLAS BDirector 2014-08-15Sell5,000$13.9-58.49 view
Myszkowski Kenneth AllenCFO 2014-08-15Sell40,000$14.02-58.84 view
McKenney CharlesDirector 2014-06-09Sell22,000$14.32-59.71 view
Myszkowski Kenneth AllenCFO 2014-02-12Sell16,000$18.77-69.26 view

Quarterly/Annual Reports about ARWR:

News about ARWR:

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Reports Third Quarter Fiscal 2009 Financial Results Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
4 Biotechs Piper Jaffray Is Buying On The Pullback Aug 26 2015
ARWR: Update on Fiscal Third Quarter Financials Aug 17 2015
ARROWHEAD RESEARCH CORP Financials Aug 11 2015
10-Q for Arrowhead Research Corp. Aug 06 2015
Arrowhead to Present at Jefferies 2015 Hepatitis B Summit Aug 05 2015
Edited Transcript of ARWR earnings conference call or presentation 4-Aug-15 8:30pm GMT Aug 04 2015
Arrowhead Research reports 3Q loss Aug 04 2015
Arrowhead Research reports 3Q loss Aug 04 2015
Arrowhead Research Corp Earnings Call scheduled for 4:30 pm ET today Aug 04 2015
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2015
Arrowhead Reports Fiscal 2015 Third Quarter Financial Results Aug 04 2015
Q3 2015 Arrowhead Research Corp Earnings Release - After Market Close Aug 04 2015
Biotech Sector Review Aug 04 2015
Arrowhead to Report Fiscal 2015 Third Quarter Financial Results Jul 28 2015
Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand Jul 08 2015
Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency Jul 02 2015
Can Hepatitis B Be A Blockbuster Bug? Jul 01 2015
Edited Transcript of ARWR earnings conference call or presentation 11-May-15 8:30pm GMT Jun 19 2015
Arrowhead Research (ARWR) Stock Gains as Germany Clears Further HBV Tests Jun 17 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

Truthtracer@twitter
ReplyTruthtracer@twitter - 1 year ago
Correction, carefully read the scientific foundation shared in the 4th quarter report.
Truthtracer@twitter
ReplyTruthtracer@twitter - 1 year ago
Pay attention to the science in the third quarter report. Institutional holdings have increased from 30% to over 70% in 3 months. Reputable, longer term holders...
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK